Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) confirms that its expanded GenoType multi-risk test, including three new diseases – pancreatic cancer, melanoma and atrial fibrillation – is now available to order in Australia. Is. Expanded testing launched in the US in March.
The Genotype Multi-Risk Test now provides a total of nine individual serious disease risk assessments, all from a simple saliva sample and for people of most ethnicities over the age of 30.
This approval by the National Association of Testing Authorities (NATA) follows approval in March this year by the Centers for Medicare & Medicaid (CMS) to sell the expanded panel in the United States.
Simon Morris, CEO of Genetic Technologies, said, “Receiving approval to sell the expanded version of MultiTest in Australia is a great way to fulfill our commitment to be the world leader in providing personalized risk assessment to enable preventive health care for many serious diseases. “Unleashes the potential of GTG.”
Testing for three more diseases
The Genotype Multi-Risk Assessment Panel focuses on oncology, cardiovascular and metabolic diseases, including breast cancer, ovarian cancer, prostate cancer, colorectal cancer, diabetes and coronary artery disease. Now atrial fibrillation, melanoma and pancreatic cancer have been added to that list.
Each new disease recognized recently causes significant mortality and morbidity. According to the Australian Institute of Health and Welfare, there will be approximately 10,639 new cases of melanoma in 2023, making it Australia’s third most commonly diagnosed cancer.
The prognosis for pancreatic cancer is even more dire, in Australia it is estimated that in 2023, 2,355 people will be diagnosed with pancreatic cancer and 87% of these will die. In both cases, identifying those at increased risk provides the opportunity for early diagnosis and early intervention, which significantly improves patient outcomes, increases life expectancy and saves lives.
In the case of atrial fibrillation (AFib), surveys and studies on sections of the Australian population show that AFib affects approximately 2% of the general population, which equates to over 500,000 people.